<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851916</url>
  </required_header>
  <id_info>
    <org_study_id>CK Recurrent Prostate SD</org_study_id>
    <nct_id>NCT00851916</nct_id>
  </id_info>
  <brief_title>CyberKnife Radiosurgery for Locally Recurrent Prostate CA</brief_title>
  <official_title>VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CyberKnife Centers of San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CyberKnife Centers of San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to scientifically evaluate the effects (good and bad) of a new&#xD;
      type of radiation treatment in patients with locally recurrent prostate cancer after prior&#xD;
      radiotherapy. The treatment is known as prostate radiosurgery, and is distinguished from&#xD;
      traditional radiotherapy by the application of smaller, more precisely controlled margins&#xD;
      around the area targeted for full dose radiation, and far fewer treatments, using a much&#xD;
      larger dose per treatment.&#xD;
&#xD;
      This research is being done to see what advantages, if any, prostate radiosurgery may have&#xD;
      over other salvage treatment methods, including brachytherapy, cryosurgery, high intensity&#xD;
      focused ultrasound (HIFU), hormonal therapy and radical prostatectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish pattern of PSA decline</measure>
    <time_frame>Post CyberKnife Radiosurgery - 5 year f/up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life realitive to other commonly used radiation treatment methods for recurrent prostate cancer</measure>
    <time_frame>Post CyberKnife Radiosurgery/5 yr. f/up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Radiosurgery</intervention_name>
    <description>CyberKnife Radiosurgery</description>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage T1 -&#xD;
             T3 (AJCC 6th Edition, see Appendix II), NX/N0, M0, following prior prostate&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Karnofsky performance status &gt;80.&#xD;
&#xD;
          -  Greater than 5 year life expectancy&#xD;
&#xD;
          -  Greater than 2 years since the original course of radiotherapy.&#xD;
&#xD;
          -  Absence of distant metastases by radiologic or pathologic assessment.&#xD;
&#xD;
          -  Absence of lymph node involvement by radiologic or pathologic assessment.&#xD;
&#xD;
          -  Patients must sign a study-specific informed consent form prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage T4 disease (AJCC 6th Edition, see Appendix II).&#xD;
&#xD;
          -  Less than 2 years since the original course of radiotherapy.&#xD;
&#xD;
          -  Lymph node involvement (N1).&#xD;
&#xD;
          -  Evidence of distant metastases (M1).&#xD;
&#xD;
          -  Radical surgery for carcinoma of the prostate&#xD;
&#xD;
          -  Previous or concurrent cancers other than basal, in situ, or squamous cell skin&#xD;
             cancers unless disease-free for â‰¥ 5 years.&#xD;
&#xD;
          -  Major medical or psychiatric illness, which in the investigator's opinion, would&#xD;
             prevent completion of treatment and would interfere with follow-up.&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  Late GI or GU Morbidity &gt; Grade 1 from the prior course of radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B Fuller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CyberKnife Centers of San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlyn Tripp</last_name>
    <phone>619-230-0400</phone>
    <phone_ext>224</phone_ext>
    <email>ctripp@rmgmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CybeKnife Centers of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Donald B. Fuller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CyberKnife Centers of San Diego</investigator_affiliation>
    <investigator_full_name>Carlyn Tripp</investigator_full_name>
    <investigator_title>Donald Fuller, M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

